Difference between revisions of "Dabigatran (Pradaxa)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (22 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Competitive direct thrombin inhibitor. | + | Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.<ref name="insert">[https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Dabigatran (Pradaxa) package insert]</ref><ref>[[:File:Dabigatran.pdf | Dabigatran (Pradaxa) package insert (locally hosted backup)]]</ref><ref>[http://www.pradaxa.com Pradaxa manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Reversal information== | ||
| + | [[Idarucizumab (Praxbind)]] can rapidly and completely reverse the effects of dabigatran as measured by normalization of dilute thrombin time. | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *Atrial fibrillation | ||
| + | *[[Venous thromboembolism]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf Dabigatran (Pradaxa) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dabigatran-patient-drug-information Dabigatran (Pradaxa) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2008-03-17: Initial authorization | ||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Pradax, Pradaxa, Prazaxa | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | [[Category:Direct oral anticoagulants]] | ||
| + | [[Category:Direct thrombin inhibitors]] | ||
| + | |||
| + | [[Category:Venous thromboembolism medications]] | ||
| + | |||
| + | [[Category:EMA approved in 2008]] | ||
| + | [[Category:FDA approved in 2010]] | ||
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism: Competitive direct thrombin inhibitor. Inhibition of thrombin, a serine protease, inhibits the conversion of fibrinogen into fibrin in the coagulation cascade and subsequent development of thrombus. Dabigatran inhibits free thrombin, clot-bound thrombin, and thrombin-induced platelet aggregation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Reversal information
Idarucizumab (Praxbind) can rapidly and completely reverse the effects of dabigatran as measured by normalization of dilute thrombin time.
Diseases for which it is used
- Atrial fibrillation
- Venous thromboembolism
Patient drug information
History of changes in EMA indication
- 2008-03-17: Initial authorization
Also known as
- Brand names: Pradax, Pradaxa, Prazaxa